Posted by Michael Wonder on 25 Nov 2022
Junshi Biosciences announces submission of a marketing authorisation application for toripalimab to the UK MHRA
24 November 2022 - Second marketing authorisation application submission in Europe reflects toripalimab’s steady yet speedy progress towards global commercialisation.
Shanghai Junshi Biosciences announced today that the company has submitted a marketing authorisation application to the United Kingdom’s MHRA for toripalimab.
